Based on the effects that social distancing and quarantine are having on current and upcoming clinical studies, decentralization offers many benefits over the traditional approach to clinical trial execution – leveraging digital technology and home health to facilitate site-less trials and patient-centric protocols.
To our #sitepartners on the front lines, from all of us at Biorasi, thank you for everything you do to bring critical treatments to patients as we face #COVID19 together.
In this time of uncertainty caused by the COVID-19 pandemic, the importance of delivering new treatments to patients as quickly as possible has never been more vital. Without a proactive and comprehensive strategy in place to manage clinical trials over the coming weeks and maybe months, consequences may be severe –especially for those that need the treatment the most.
Digital technology’s presence in the healthcare industry continues to grow, expanding across diagnostic and therapeutic treatments in precision medicine. Biorasi was on-site to witness these advancements and innovations at this year’s Molecular Med Tri-Con.
With digital therapeutics experiencing an evolution, Biorasi was on hand at DTx West 2020 to highlight the importance of evidence as a differentiator in clinical trials. Read more about our event experience >>
As digital therapeutics are integrated into every aspect of the healthcare landscape, patients, payers, and providers are seeing an increasingly complex set of software-driven therapy options reaching the market. This rapidly expanding field has enormous potential but faces challenges at every stage, from design to patient perception. Focusing on the clinical trial stage, how does the trial of a digital therapeutic compare to that of a pharmaceutical? What are the specific challenges of running a digital therapeutics clinical trial, and how can sponsors adapt their approach for the highest chance of success?
